<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35499795</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1182</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Molecular neurobiology</Title><ISOAbbreviation>Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>The Role of TDP-43 in Neurodegenerative Disease.</ArticleTitle><Pagination><StartPage>4223</StartPage><EndPage>4241</EndPage><MedlinePgn>4223-4241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12035-022-02847-x</ELocationID><Abstract><AbstractText>In recent years, more and more neurodegenerative diseases, such as ALS, FTLD and AD, have been found to share a common pathological feature, which is the depletion of TDP-43 in the nucleus and the accumulation of TDP-43 in the cytoplasm through hyperphosphorylation, ubiquitination and cleavage. Therefore, this kind of neurodegenerative disease is also called TDP-43 proteinopathy. This suggests that TDP-43 plays a role in the pathogenesis of disease. Current studies show that the pathophysiological mechanism of TDP-43 in neurodegeneration is very complex. In this review, we describe the structure of TDP-43, its main physiological functions, the possible pathogenesis and how TDP-43 provides a new pathway to treat neurodegenerative diseases.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Yan-Zhe</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, Chengde Medical University Affiliated Hospital, Chengde Medical University, Anyuan Road, Chengde, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chengde Medical University Affiliated Hospital, Chengde Medical University, No.36 Nanyingzi Road, Chengde, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dou</LastName><ForeName>Jie-Zhi</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chengde Medical University Affiliated Hospital, Chengde Medical University, No.36 Nanyingzi Road, Chengde, People's Republic of China. cyfydzj@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Neurobiol</MedlineTA><NlmUniqueID>8900963</NlmUniqueID><ISSNLinking>0893-7648</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054875" MajorTopicYN="N">Ubiquitination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TDP-43 proteinopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>2</Day><Hour>11</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35499795</ArticleId><ArticleId IdType="doi">10.1007/s12035-022-02847-x</ArticleId><ArticleId IdType="pii">10.1007/s12035-022-02847-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin-Asp PG et al (2018) TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci 21(2):228&#x2013;239. https://doi.org/10.1038/s41593-017-0047-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId><ArticleId IdType="pmc">5800968</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE (2015) TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics 12(2):352&#x2013;363. https://doi.org/10.1007/s13311-015-0338-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0338-x</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId><ArticleId IdType="pmc">4404432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Mullane PC, Periz G, Wang J (2011) TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet 20(10):1952&#x2013;1965. https://doi.org/10.1093/hmg/ddr076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr076</ArticleId><ArticleId IdType="pubmed">21355045</ArticleId><ArticleId IdType="pmc">3080607</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JC, Morton DB (2017) Drosophila lines with mutant and wild type human TDP-43 replacing the endogenous gene reveals phosphorylation and ubiquitination in mutant lines in the absence of viability or lifespan defects. PLoS ONE 12(7):e0180828. https://doi.org/10.1371/journal.pone.0180828</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180828</ArticleId><ArticleId IdType="pubmed">28686708</ArticleId><ArticleId IdType="pmc">5501610</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 13:867&#x2013;878. https://doi.org/10.2741/2727</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2727</ArticleId><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V, Tosat-Bitrian C, Nozal V, Nagaraj S, Martin-Requero A, Martinez A (2019) TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chem Neurosci 10(3):1183&#x2013;1196. https://doi.org/10.1021/acschemneuro.9b00026</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00026</ArticleId><ArticleId IdType="pubmed">30785719</ArticleId></ArticleIdList></Reference><Reference><Citation>Birsa N, Bentham MP, Fratta P (2020) Cytoplasmic functions of TDP-43 and FUS and their role in ALS. Semin Cell Dev Biol 99:193&#x2013;201. https://doi.org/10.1016/j.semcdb.2019.05.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.05.023</ArticleId><ArticleId IdType="pubmed">31132467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Gu D, Meng M, Gordon ML (2020) TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer&#x2019;s Disease. Front Aging Neurosci 12:166. https://doi.org/10.3389/fnagi.2020.00166</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00166</ArticleId><ArticleId IdType="pubmed">32581773</ArticleId><ArticleId IdType="pmc">7287025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, Devoy A, Fratta P, Fisher EMC, Talbot K, Schiavo G (2020) Mice Carrying ALS Mutant TDP-43, but Not Mutant FUS, Display In Vivo Defects in Axonal Transport of Signaling Endosomes. Cell Rep 30(11):3655-3662.e3652. https://doi.org/10.1016/j.celrep.2020.02.078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.02.078</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId><ArticleId IdType="pmc">7090381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T, Song B, Lee IS (2020) Drosophila Glia: Models for Human Neurodevelopmental and Neurodegenerative Disorders. Int J Mol Sci 21 (14). doi: https://doi.org/10.3390/ijms21144859</Citation></Reference><Reference><Citation>Clark JA, Yeaman EJ, Blizzard CA, Chuckowree JA, Dickson TC (2016) A Case for Microtubule Vulnerability in Amyotrophic Lateral Sclerosis: Altered Dynamics During Disease. Front Cell Neurosci 10:204. https://doi.org/10.3389/fncel.2016.00204</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00204</ArticleId><ArticleId IdType="pubmed">27679561</ArticleId><ArticleId IdType="pmc">5020100</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry DM, Devine SE (2019) Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders. Front Genet 10:1244. https://doi.org/10.3389/fgene.2019.01244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.01244</ArticleId><ArticleId IdType="pubmed">31969897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D&#x2019;Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE (2008) Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci 121(Pt 22):3778&#x2013;3785. https://doi.org/10.1242/jcs.038950</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling AL (1868) Shorter J (2021) Combating deleterious phase transitions in neurodegenerative disease. Biochim Biophys Acta Mol Cell Res 5:118984. https://doi.org/10.1016/j.bbamcr.2021.118984</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.118984</ArticleId></ArticleIdList></Reference><Reference><Citation>Floare ML, Allen SP (2020) Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis. Neurosci Insights 15:2633105520957302. https://doi.org/10.1177/2633105520957302</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2633105520957302</ArticleId><ArticleId IdType="pubmed">32995749</ArticleId><ArticleId IdType="pmc">7503004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, Jiang S, Ma X et al (2016) The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med 22(8):869&#x2013;878. https://doi.org/10.1038/nm.4130</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId><ArticleId IdType="pmc">4974139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR, Vourc&#x2019;h P, Andres CR, Corcia P, Lanznaster D, Blasco H (2019) The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain 142(5):1176&#x2013;1194. https://doi.org/10.1093/brain/awz078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId><ArticleId IdType="pmc">6487324</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E (2020) Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol. https://doi.org/10.1111/bph.15148</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem 283(19):13302&#x2013;13309. https://doi.org/10.1074/jbc.M800342200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId><ArticleId IdType="pmc">2442318</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem 276(39):36337&#x2013;36343. https://doi.org/10.1074/jbc.M104236200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne AN, Zaepfel BL, Zarnescu DC (2017) Failure to Deliver and Translate-New Insights into RNA Dysregulation in ALS. Front Cell Neurosci 11:243. https://doi.org/10.3389/fncel.2017.00243</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00243</ArticleId><ArticleId IdType="pubmed">28860970</ArticleId><ArticleId IdType="pmc">5562674</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB, Almeida S, Lopez-Gonzalez R (2017) Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. Embo j 36(20):2931&#x2013;2950. https://doi.org/10.15252/embj.201797568</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201797568</ArticleId><ArticleId IdType="pubmed">28916614</ArticleId><ArticleId IdType="pmc">5641681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Buratti E (2016) Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J Neurochem 138(Suppl 1):95&#x2013;111. https://doi.org/10.1111/jnc.13625</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13625</ArticleId><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, Whelan DR, Jamali MS, Perri E, Shahheydari H, Toth RP, Parakh S, Robinson T et al (2020) Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol Neurodegener 15(1):51. https://doi.org/10.1186/s13024-020-00386-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00386-4</ArticleId><ArticleId IdType="pubmed">32907630</ArticleId><ArticleId IdType="pmc">7488163</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies JE, Shkreta L, Moszczynski AJ, Sidib&#xe9; H, Semmler S, Fouillen A, Bennett ER, Bekenstein U et al (2018) TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain 141(5):1320&#x2013;1333. https://doi.org/10.1093/brain/awy062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy062</ArticleId><ArticleId IdType="pubmed">29562314</ArticleId><ArticleId IdType="pmc">5917749</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham J, Keon M, Brennan S, Saksena N (2020) Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst A Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy. Int J Mol Sci 21 (10). doi: https://doi.org/10.3390/ijms21103464</Citation></Reference><Reference><Citation>Russo A, Scardigli R, La Regina F, Murray ME, Romano N, Dickson DW, Wolozin B, Cattaneo A et al (2017) Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Hum Mol Genet 26(8):1407&#x2013;1418. https://doi.org/10.1093/hmg/ddx035</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx035</ArticleId><ArticleId IdType="pubmed">28158562</ArticleId><ArticleId IdType="pmc">6075552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avenda&#xf1;o-V&#xe1;zquez SE, Dhir A, Romano M, D&#x2019;Ambrogio A, Tollervey J, Ule J et al (2011) TDP-43 regulates its mRNA levels through a negative feedback loop. Embo j 30(2):277&#x2013;288. https://doi.org/10.1038/emboj.2010.310</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.310</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F (2021) Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nat Rev Neurosci 22(4):197&#x2013;208. https://doi.org/10.1038/s41583-021-00431-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00431-1</ArticleId><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B, Lee BL, Shorter J (2021) FUS and TDP-43 Phases in Health and Disease. Trends Biochem Sci. https://doi.org/10.1016/j.tibs.2020.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2020.12.005</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId><ArticleId IdType="pmc">8195841</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P et al (2020) TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-322983</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-322983</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, Chew YL, Lum JS, Geraghty NJ, Yerbury JJ, Cashman NR (2020) Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises. Front Cell Neurosci 14:581907. https://doi.org/10.3389/fncel.2020.581907</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.581907</ArticleId><ArticleId IdType="pubmed">33328890</ArticleId><ArticleId IdType="pmc">7671971</ArticleId></ArticleIdList></Reference><Reference><Citation>Layalle S, They L, Ourghani S, Raoul C, Soustelle L (2021) Amyotrophic Lateral Sclerosis Genes in Drosophila melanogaster. Int J Mol Sci 22 (2). doi: https://doi.org/10.3390/ijms22020904</Citation></Reference><Reference><Citation>Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, Tang W, Winton MJ et al (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30(22):7729&#x2013;7739. https://doi.org/10.1523/jneurosci.5894-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.5894-09.2010</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId><ArticleId IdType="pmc">2890254</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L, Fr&#xe9;bourg T, Campion D, Lecourtois M (2011) Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol Dis 41(2):398&#x2013;406. https://doi.org/10.1016/j.nbd.2010.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.10.007</ArticleId><ArticleId IdType="pubmed">20951205</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA 3rd, Fushimi K et al (2010) A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A 107(7):3169&#x2013;3174. https://doi.org/10.1073/pnas.0913602107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0913602107</ArticleId><ArticleId IdType="pubmed">20133767</ArticleId><ArticleId IdType="pmc">2840283</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes PS, Boehringer A, Zwick R, Tang JE, Grigsby B, Zarnescu DC (2011) Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum Mol Genet 20(12):2308&#x2013;2321. https://doi.org/10.1093/hmg/ddr124</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr124</ArticleId><ArticleId IdType="pubmed">21441568</ArticleId><ArticleId IdType="pmc">3098735</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazelett DJ, Chang JC, Lakeland DL, Morton DB (2012) Comparison of parallel high-throughput RNA sequencing between knockout of TDP-43 and its overexpression reveals primarily nonreciprocal and nonoverlapping gene expression changes in the central nervous system of Drosophila. G3 (Bethesda) 2 (7):789&#x2013;802. doi: https://doi.org/10.1534/g3.112.002998</Citation></Reference><Reference><Citation>Romano M, Feiguin F, Buratti E (2012) Drosophila Answers to TDP-43 Proteinopathies. J Amino Acids 2012:356081. https://doi.org/10.1155/2012/356081</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/356081</ArticleId><ArticleId IdType="pubmed">22577517</ArticleId><ArticleId IdType="pmc">3337594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Ferris J, Gao FB (2009) Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol Brain 2:30. https://doi.org/10.1186/1756-6606-2-30</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-2-30</ArticleId><ArticleId IdType="pubmed">19781077</ArticleId><ArticleId IdType="pmc">2762964</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y, Yamada S (2020) A novel hypothesis on metal dyshomeostasis and mitochondrial dysfunction in amyotrophic lateral sclerosis: Potential pathogenetic mechanism and therapeutic implications. Eur J Pharmacol:173737. doi: https://doi.org/10.1016/j.ejphar.2020.173737</Citation></Reference><Reference><Citation>Huang C, Yan S, Zhang Z (2020) Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases. Transl Neurodegener 9(1):40. https://doi.org/10.1186/s40035-020-00219-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00219-w</ArticleId><ArticleId IdType="pubmed">33126923</ArticleId><ArticleId IdType="pmc">7597011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X (2018) Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. https://doi.org/10.1111/jnc.14327</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pubmed">29524228</ArticleId><ArticleId IdType="pmc">6110993</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren SA, Galvis-Escobar S, Abisambra JF (2020) Tau-mediated dysregulation of RNA: Evidence for a common molecular mechanism of toxicity in frontotemporal dementia and other tauopathies. Neurobiol Dis 141:104939. https://doi.org/10.1016/j.nbd.2020.104939</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104939</ArticleId><ArticleId IdType="pubmed">32413399</ArticleId><ArticleId IdType="pmc">7397812</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ et al (2017) Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544(7650):367&#x2013;371. https://doi.org/10.1038/nature22038</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId><ArticleId IdType="pmc">5642042</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt MF, Gan ZY, Komander D, Dewson G (2021) Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death Differ. https://doi.org/10.1038/s41418-020-00706-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00706-7</ArticleId><ArticleId IdType="pubmed">33414510</ArticleId><ArticleId IdType="pmc">7862249</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera-Cruz MS, Simmen T (2017) Of yeast, mice and men: MAMs come in two flavors. Biol Direct 12(1):3. https://doi.org/10.1186/s13062-017-0174-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13062-017-0174-5</ArticleId><ArticleId IdType="pubmed">28122638</ArticleId><ArticleId IdType="pmc">5267431</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC (2020) The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener 15(1):45. https://doi.org/10.1186/s13024-020-00397-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId><ArticleId IdType="pmc">7429473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Shanware NP, Bowler MJ, Tibbetts RS (2010) Amyotrophic lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a common biochemical complex to co-regulate HDAC6 mRNA. J Biol Chem 285(44):34097&#x2013;34105. https://doi.org/10.1074/jbc.M110.154831</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.154831</ArticleId><ArticleId IdType="pubmed">20720006</ArticleId><ArticleId IdType="pmc">2962508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna S, Esposito S, Masala A, Sini P, Nieddu G, Galioto M, Fais M, Iaccarino C et al (2020) HDAC1 inhibition ameliorates TDP-43-induced cell death in vitro and in vivo. Cell Death Dis 11(5):369. https://doi.org/10.1038/s41419-020-2580-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2580-3</ArticleId><ArticleId IdType="pubmed">32409664</ArticleId><ArticleId IdType="pmc">7224392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M, Song J (2020) ALS-causing D169G mutation disrupts the ATP-binding capacity of TDP-43 RRM1 domain. Biochem Biophys Res Commun 524(2):459&#x2013;464. https://doi.org/10.1016/j.bbrc.2020.01.122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.01.122</ArticleId><ArticleId IdType="pubmed">32007267</ArticleId></ArticleIdList></Reference><Reference><Citation>Prakash A, Kumar V, Banerjee A, Lynn AM, Prasad R (2020) Structural heterogeneity in RNA recognition motif 2 (RRM2) of TAR DNA-binding protein 43 (TDP-43): clue to amyotrophic lateral sclerosis. J Biomol Struct Dyn:1&#x2013;11. doi: https://doi.org/10.1080/07391102.2020.1714481</Citation></Reference><Reference><Citation>Feiler MS, Strobel B, Freischmidt A, Helferich AM, Kappel J, Brewer BM, Li D, Thal DR et al (2015) TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol 211(4):897&#x2013;911. https://doi.org/10.1083/jcb.201504057</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201504057</ArticleId><ArticleId IdType="pubmed">26598621</ArticleId><ArticleId IdType="pmc">4657165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nay K, Smiles WJ, Kaiser J, McAloon LM, Loh K, Galic S, Oakhill JS, Gundlach AL, et al (2021) Molecular Mechanisms Underlying the Beneficial Effects of Exercise on Brain Function and Neurological Disorders. Int J Mol Sci 22 (8). doi: https://doi.org/10.3390/ijms22084052</Citation></Reference><Reference><Citation>Liu G, Byrd A, Warner AN, Pei F, Basha E, Buchanan A, Buchan JR (2020) Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover. Mol Cell Biol 40 (4). doi: https://doi.org/10.1128/mcb.00256-19</Citation></Reference><Reference><Citation>Nonaka T, Hasegawa M (2020) Prion-like properties of assembled TDP-43. Curr Opin Neurobiol 61:23&#x2013;28. https://doi.org/10.1016/j.conb.2019.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.11.018</ArticleId><ArticleId IdType="pubmed">31862626</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, Risse E, Tyzack GE, Mitchell JS, Taha DM, Chen YR, Newcombe J, Collinge J et al (2020) Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain 143(2):430&#x2013;440. https://doi.org/10.1093/brain/awz419</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId><ArticleId IdType="pmc">7009461</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, Kawai K, Takagi S et al (2016) Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain 139(Pt 12):3187&#x2013;3201. https://doi.org/10.1093/brain/aww237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww237</ArticleId><ArticleId IdType="pubmed">27679482</ArticleId><ArticleId IdType="pmc">5840881</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, Callegaro S, Corbelli A, Fiordaliso F, Ferrara D, Brunelli L, Sestito G, Pastorelli R et al (2021) Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. Mol Neurodegener 16(1):52. https://doi.org/10.1186/s13024-021-00470-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00470-3</ArticleId><ArticleId IdType="pubmed">34376243</ArticleId><ArticleId IdType="pmc">8353748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusamoto T, Nishihara H (2018) Efficiency breakthrough for radical LEDs. Nature 563(7732):480&#x2013;481. https://doi.org/10.1038/d41586-018-07394-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-018-07394-x</ArticleId><ArticleId IdType="pubmed">30464278</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan AT, Malik MA, Rahman S, Yeo HR, Lee EJ, Abdullah TS, Choi I (2017) Perspective Insights of Exosomes in Neurodegenerative Diseases: A Critical Appraisal. Front Aging Neurosci 9:317. https://doi.org/10.3389/fnagi.2017.00317</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00317</ArticleId><ArticleId IdType="pubmed">29033828</ArticleId><ArticleId IdType="pmc">5626860</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Pei L, Yao S, Wu Y, Shang Y (2017) NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies. Front Cell Neurosci 11:63. https://doi.org/10.3389/fncel.2017.00063</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00063</ArticleId><ArticleId IdType="pubmed">28337127</ArticleId><ArticleId IdType="pmc">5343070</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Tzioras M, Paolicelli RC (2019) Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration. Front Cell Neurosci 13:63. https://doi.org/10.3389/fncel.2019.00063</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00063</ArticleId><ArticleId IdType="pubmed">30863284</ArticleId><ArticleId IdType="pmc">6399113</ArticleId></ArticleIdList></Reference><Reference><Citation>Strohm L, Behrends C (2020) Glia-specific autophagy dysfunction in ALS. Semin Cell Dev Biol 99:172&#x2013;182. https://doi.org/10.1016/j.semcdb.2019.05.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.05.024</ArticleId><ArticleId IdType="pubmed">31132469</ArticleId></ArticleIdList></Reference><Reference><Citation>Carillo MR, Bertapelle C, Scial&#xf2; F, Siervo M, Spagnuolo G, Simeone M, Peluso G, Digilio FA (2020) L-Carnitine in Drosophila: A Review. Antioxidants (Basel) 9 (12). doi: https://doi.org/10.3390/antiox9121310</Citation></Reference><Reference><Citation>Velebit J, Horvat A, Smoli&#x10d; T, Prpar Mihevc S, Rogelj B, Zorec R, Vardjan N (2020) Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca(2+) signaling and dysregulated cell metabolism. Sci Rep 10(1):6003. https://doi.org/10.1038/s41598-020-62864-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62864-5</ArticleId><ArticleId IdType="pubmed">32265469</ArticleId><ArticleId IdType="pmc">7138839</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog JJ, Xu W, Deshpande M, Rahman R, Suib H, Rodal AA, Rosbash M, Paradis S (2020) TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression. Proc Natl Acad Sci U S A 117(21):11760&#x2013;11769. https://doi.org/10.1073/pnas.1917038117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1917038117</ArticleId><ArticleId IdType="pubmed">32393629</ArticleId><ArticleId IdType="pmc">7260973</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y (2020) Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Neuropathology. https://doi.org/10.1111/neup.12644</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12644</ArticleId><ArticleId IdType="pubmed">32367540</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Oiwa K, Murata Y, Komine O, Sobue A, Endo F, Takahashi E, Yamanaka K (2020) ALS-linked TDP-43(M337V) knock-in mice exhibit splicing deregulation without neurodegeneration. Mol Brain 13(1):8. https://doi.org/10.1186/s13041-020-0550-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId><ArticleId IdType="pmc">6971932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihankaya H, Theiss C, Matschke V (2021) Little Helpers or Mean Rogue-Role of Microglia in Animal Models of Amyotrophic Lateral Sclerosis. Int J Mol Sci 22 (3). doi: https://doi.org/10.3390/ijms22030993</Citation></Reference><Reference><Citation>Yamashita S, Ando Y (2015) Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl Neurodegener 4:13. https://doi.org/10.1186/s40035-015-0036-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId><ArticleId IdType="pmc">4513711</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B et al (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323(5918):1208&#x2013;1211. https://doi.org/10.1126/science.1165942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId><ArticleId IdType="pmc">4516382</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Libon DJ, Toledo JB, Xie SX, McCluskey L, Elman L, Geser F, Lee VM et al (2012) Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol 123(3):395&#x2013;407. https://doi.org/10.1007/s00401-011-0932-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0932-x</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId><ArticleId IdType="pmc">3595560</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74(1):20&#x2013;38. https://doi.org/10.1002/ana.23937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId><ArticleId IdType="pmc">3785076</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Arai K, Del Tredici K, Toledo JB, Robinson JL, Lee EB, Kuwabara S, Shibuya K et al (2014) TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol 128(3):423&#x2013;437. https://doi.org/10.1007/s00401-014-1299-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1299-6</ArticleId><ArticleId IdType="pubmed">24916269</ArticleId><ArticleId IdType="pmc">4384652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong P, Ho WY, Yen YC, Sanford E, Ling SC (2020) The vulnerability of motor and frontal cortex-dependent behaviors in mice expressing ALS-linked mutation in TDP-43. Neurobiol Aging 92:43&#x2013;60. https://doi.org/10.1016/j.neurobiolaging.2020.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.03.019</ArticleId><ArticleId IdType="pubmed">32422502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer MS, Reale LA, Lewis KE, Walker AK, Dickson TC, Woodhouse A, Blizzard CA (2020) Amyotrophic lateral sclerosis associated mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex. J Neurochem. https://doi.org/10.1111/jnc.15214</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15214</ArticleId><ArticleId IdType="pubmed">33064315</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K (2013) Amyotrophic lateral sclerosis&#x2013;a model of corticofugal axonal spread. Nat Rev Neurol 9(12):708&#x2013;714. https://doi.org/10.1038/nrneurol.2013.221</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.221</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId><ArticleId IdType="pmc">3943211</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, Wu LC, Ding M et al (2017) Toxic PR(n) poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A 114(7):E1111-e1117. https://doi.org/10.1073/pnas.1620293114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1620293114</ArticleId><ArticleId IdType="pubmed">28069952</ArticleId><ArticleId IdType="pmc">5320981</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Barmada SJ (2018) TDP43 and RNA instability in amyotrophic lateral sclerosis. Brain Res 1693(Pt A):67&#x2013;74. https://doi.org/10.1016/j.brainres.2018.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.01.015</ArticleId><ArticleId IdType="pubmed">29395044</ArticleId><ArticleId IdType="pmc">5997512</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Alberici A, Samra K, Russell LL, Greaves CV, Bocchetta M, Ducharme S, Finger E et al (2021) Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimers Dement. https://doi.org/10.1002/alz.12485</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12485</ArticleId><ArticleId IdType="pubmed">34874596</ArticleId></ArticleIdList></Reference><Reference><Citation>Clos AL, Kayed R, Lasagna-Reeves CA (2012) Association of skin with the pathogenesis and treatment of neurodegenerative amyloidosis. Front Neurol 3:5. https://doi.org/10.3389/fneur.2012.00005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2012.00005</ArticleId><ArticleId IdType="pubmed">22319507</ArticleId><ArticleId IdType="pmc">3262151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam M (2013) Primary progressive aphasia: A dementia of the language network. Dement Neuropsychol 7(1):2&#x2013;9. https://doi.org/10.1590/s1980-57642013dn70100002</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s1980-57642013dn70100002</ArticleId><ArticleId IdType="pubmed">24707349</ArticleId><ArticleId IdType="pmc">3975615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Iglesias Espinosa MDM, Lashley T, Warren JD, Rohrer JD (2020) In vivo staging of frontotemporal lobar degeneration TDP-43 type C pathology. Alzheimers Res Ther 12(1):34. https://doi.org/10.1186/s13195-020-00600-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00600-x</ArticleId><ArticleId IdType="pubmed">32220237</ArticleId><ArticleId IdType="pmc">7102433</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ, Dearmond SJ, Miller BL et al (2010) TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 75(24):2204&#x2013;2211. https://doi.org/10.1212/WNL.0b013e318202038c</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318202038c</ArticleId><ArticleId IdType="pubmed">21172843</ArticleId><ArticleId IdType="pmc">3013589</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, Fang L, Van Deerlin VM et al (2014) Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 127(3):423&#x2013;439. https://doi.org/10.1007/s00401-013-1238-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId><ArticleId IdType="pmc">3971993</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Schoor E, Koper MJ, Ospitalieri S, Dedeene L, Tom&#xe9; SO, Vandenberghe R, Brenner D, Otto M et al (2020) Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathol Appl Neurobiol. https://doi.org/10.1111/nan.12668</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12668</ArticleId><ArticleId IdType="pubmed">32949047</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaca G, Martinez-Gonzalez L, Fernandez A, Rojas-Prats E, Porras G, Cuevas EP, Gil C, Martinez A et al (2020) Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). J Neurochem. https://doi.org/10.1111/jnc.15118</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15118</ArticleId><ArticleId IdType="pubmed">32628315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, Buratti E, Baralle F, Bailey R, Pickering-Brown S, Dickson D et al (2007) Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27(39):10530&#x2013;10534. https://doi.org/10.1523/jneurosci.3421-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.3421-07.2007</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId><ArticleId IdType="pmc">6673167</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR (2012) Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8(8):423&#x2013;434. https://doi.org/10.1038/nrneurol.2012.117</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.117</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId><ArticleId IdType="pmc">3629543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Hu W, Tan X, Qu S, Chu D, Gong CX, Iqbal K, Liu F (2020) Elevation of casein kinase 1&#x3b5; associated with TDP-43 and tau pathologies in Alzheimer&#x2019;s disease. Brain Pathol 30(2):283&#x2013;297. https://doi.org/10.1111/bpa.12775</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12775</ArticleId><ArticleId IdType="pubmed">31376192</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, Brown J, Anderson-Jackson L, et al (2021) Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. Brain Sci 11 (2). doi: https://doi.org/10.3390/brainsci11020215</Citation></Reference><Reference><Citation>Gao J, Wang L, Gao C, Arakawa H, Perry G (1866) Wang X (2020) TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer&#x2019;s disease. Biochim Biophys Acta Mol Basis Dis 1:165580. https://doi.org/10.1016/j.bbadis.2019.165580</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2019.165580</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan EP, Duffy JR, Whitwell JL, Vemuri P, Dickson DW, Josephs KA (2016) Mixed tau and TDP-43 pathology in a patient with unclassifiable primary progressive aphasia. Neurocase 22(1):55&#x2013;59. https://doi.org/10.1080/13554794.2015.1041534</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13554794.2015.1041534</ArticleId><ArticleId IdType="pubmed">25929342</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW (2016) TDP-43 in the olfactory bulb in Alzheimer&#x2019;s disease. Neuropathol Appl Neurobiol 42(4):390&#x2013;393. https://doi.org/10.1111/nan.12309</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12309</ArticleId><ArticleId IdType="pubmed">26810591</ArticleId><ArticleId IdType="pmc">5154242</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA (2016) TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain 139(11):2983&#x2013;2993. https://doi.org/10.1093/brain/aww224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId><ArticleId IdType="pmc">5091047</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC et al (2016) Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol 131(4):571&#x2013;585. https://doi.org/10.1007/s00401-016-1537-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId><ArticleId IdType="pmc">5946692</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, Ross OA, Dickson DW (2015) Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol 129(1):53&#x2013;64. https://doi.org/10.1007/s00401-014-1358-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1358-z</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Wennberg AM, Weigand SD, Murray ME, Senjem ML, Spychalla AJ, Boeve BF, Knopman DS et al (2020) Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer&#x2019;s Disease Neuropathological Changes. J Alzheimers Dis 73(4):1511&#x2013;1523. https://doi.org/10.3233/jad-191040</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-191040</ArticleId><ArticleId IdType="pubmed">31929165</ArticleId><ArticleId IdType="pmc">7081101</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW, Nelson PT (2018) Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 28(2):264&#x2013;273. https://doi.org/10.1111/bpa.12505</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12505</ArticleId><ArticleId IdType="pubmed">28281308</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, Schneider JA (2015) Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol 77(6):942&#x2013;952. https://doi.org/10.1002/ana.24388</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24388</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId><ArticleId IdType="pmc">4447563</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L, Kleinberger G, Chapuis J, Gistelinck M, Amouyel P, Van Broeckhoven C, Lambert JC, Callaerts P et al (2015) Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiol Aging 36(2):1121&#x2013;1129. https://doi.org/10.1016/j.neurobiolaging.2014.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.09.001</ArticleId><ArticleId IdType="pubmed">25442115</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy J, Steele JC, Yu S, McCall S, Sandberg G, McGeer EG, McGeer PL (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 116(6):625&#x2013;637. https://doi.org/10.1007/s00401-008-0439-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0439-2</ArticleId><ArticleId IdType="pubmed">18843496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, Yamazaki M, Oyanagi K (2007) TDP-43 is deposited in the Guam parkinsonism-dementia brains. Brain 130(Pt 5):1386&#x2013;1394. https://doi.org/10.1093/brain/awm065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm065</ArticleId><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Winton MJ, Kwong LK, Xu Y, Xie SX, Igaz LM, Garruto RM, Perl DP et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115(1):133&#x2013;145. https://doi.org/10.1007/s00401-007-0257-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0257-y</ArticleId><ArticleId IdType="pubmed">17713769</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyanagi K, Yamazaki M, Hashimoto T, Asakawa M, Wakabayashi K, Takahashi H (2015) Hippocampal sclerosis in the parkinsonism-dementia complex of Guam: quantitative examination of neurons, neurofibrillary tangles, and TDP-43 immunoreactivity in CA1. Neuropathology 35(3):224&#x2013;235. https://doi.org/10.1111/neup.12185</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12185</ArticleId><ArticleId IdType="pubmed">25783521</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer MJ, Hulihan MM, Kachergus JM, D&#xe4;chsel JC, Stoessl AJ, Grantier LL, Calne S, Calne DB et al (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41(2):163&#x2013;165. https://doi.org/10.1038/ng.293</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.293</ArticleId><ArticleId IdType="pubmed">19136952</ArticleId><ArticleId IdType="pmc">2813485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T, Deshimaru M, Watanabe T, Kubota K, Kinoshita-Kawada M, Yuasa-Kawada J, Takasaki K, Uehara Y et al (2018) Behavioral defects in a DCTN1(G71A) transgenic mouse model of Perry syndrome. Neurosci Lett 666:98&#x2013;103. https://doi.org/10.1016/j.neulet.2017.12.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.12.038</ArticleId><ArticleId IdType="pubmed">29273399</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Wszolek ZK (2008) Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)&#x2013;a literature review. Parkinsonism Relat Disord 14(1):1&#x2013;7. https://doi.org/10.1016/j.parkreldis.2007.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2007.07.014</ArticleId><ArticleId IdType="pubmed">17870652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T, Koga S, Lin WL, Kasanuki K, Castanedes-Casey M, Wszolek ZK, Oh SJ, Tsuboi Y et al (2017) Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy. J Neuropathol Exp Neurol 76(8):676&#x2013;682. https://doi.org/10.1093/jnen/nlx049</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx049</ArticleId><ArticleId IdType="pubmed">28789478</ArticleId><ArticleId IdType="pmc">5901076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, Lechevalier B, Calne DB et al (2009) Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 15(4):281&#x2013;286. https://doi.org/10.1016/j.parkreldis.2008.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2008.07.005</ArticleId><ArticleId IdType="pubmed">18723384</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N, Neshige R, Ross OA et al (2018) Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry 89(5):482&#x2013;487. https://doi.org/10.1136/jnnp-2017-316864</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316864</ArticleId><ArticleId IdType="pubmed">29089398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosaka Y, Inoshita T, Shiba-Fukushima K, Cui C, Arano T, Imai Y, Hattori N (2017) Reduced TDP-43 Expression Improves Neuronal Activities in a Drosophila Model of Perry Syndrome. EBioMedicine 21:218&#x2013;227. https://doi.org/10.1016/j.ebiom.2017.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2017.06.002</ArticleId><ArticleId IdType="pubmed">28625517</ArticleId><ArticleId IdType="pmc">5514405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dachsel JC, Farrer MJ, Dickson DW, Tsuboi Y, Wszolek ZK (2010) Elucidating the genetics and pathology of Perry syndrome. J Neurol Sci 289(1&#x2013;2):149&#x2013;154. https://doi.org/10.1016/j.jns.2009.08.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2009.08.044</ArticleId><ArticleId IdType="pubmed">19732908</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshimaru M, Kinoshita-Kawada M, Kubota K, Watanabe T, Tanaka Y, Hirano S, Ishidate F, Hiramoto M, et al (2021) DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation. Int J Mol Sci 22 (8). doi: https://doi.org/10.3390/ijms22083985</Citation></Reference><Reference><Citation>St-Amour I, Turgeon A, Goupil C, Planel E, H&#xe9;bert SS (2018) Co-occurrence of mixed proteinopathies in late-stage Huntington&#x2019;s disease. Acta Neuropathol 135(2):249&#x2013;265. https://doi.org/10.1007/s00401-017-1786-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1786-7</ArticleId><ArticleId IdType="pubmed">29134321</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol 67(12):1159&#x2013;1165. https://doi.org/10.1097/NEN.0b013e31818e8951</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Murrell JR, Horvath S, Haraszti L, Majtenyi K, Molnar MJ, Budka H, Ghetti B et al (2009) TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 24(12):1843&#x2013;1847. https://doi.org/10.1002/mds.22697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22697</ArticleId><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Coudert L, Nonaka T, Bernard E, Hasegawa M, Schaeffer L, Leblanc P (2019) Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models. Cell Mol Life Sci 76(13):2615&#x2013;2632. https://doi.org/10.1007/s00018-019-03059-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-019-03059-8</ArticleId><ArticleId IdType="pubmed">30863908</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauffenberger A, Chitramuthu BP, Bateman A, Bennett HP, Parker JA (2013) Reduction of polyglutamine toxicity by TDP-43, FUS and progranulin in Huntington&#x2019;s disease models. Hum Mol Genet 22(4):782&#x2013;794. https://doi.org/10.1093/hmg/dds485</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds485</ArticleId><ArticleId IdType="pubmed">23172908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Chen Y, Liu M, Wang Y, Peng G (2019) TDP-43 and Limbic-Predominant Age-Related TDP-43 Encephalopathy. Front Aging Neurosci 11:376. https://doi.org/10.3389/fnagi.2019.00376</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00376</ArticleId><ArticleId IdType="pubmed">31992981</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503&#x2013;1527. https://doi.org/10.1093/brain/awz099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId><ArticleId IdType="pmc">6536849</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SH, Choi SM, Kim BC, Song WY, Kim HS, Lee KH (2020) An Autopsy-Proven Case of Limbic-Predominant Age-Related TDP-43 Encephalopathy. Yonsei Med J 61(8):731&#x2013;735. https://doi.org/10.3349/ymj.2020.61.8.731</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2020.61.8.731</ArticleId><ArticleId IdType="pubmed">32734738</ArticleId><ArticleId IdType="pmc">7393298</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ (2020) The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. https://doi.org/10.1038/s12276-020-00513-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00513-7</ArticleId><ArticleId IdType="pubmed">33311704</ArticleId><ArticleId IdType="pmc">8080766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA (2017) TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology 88(7):653&#x2013;660. https://doi.org/10.1212/wnl.0000000000003610</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000003610</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId><ArticleId IdType="pmc">5317379</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;r&#xdf; D, Kilimann I, Dyrba M, Nitsch S, Krause B, Teipel S (2020) LATE: not every dementia is Alzheimer&#x2019;s disease-Discussion of a new disease entity based on a case example&#x202f;: Current status of limbic-predominant age-related TDP-43 encephalopathy (LATE). Nervenarzt. https://doi.org/10.1007/s00115-020-00922-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00115-020-00922-z</ArticleId><ArticleId IdType="pmc">7809002</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Yu L, Nag S, Arfanakis K, Barnes LL, Bennett DA, Schneider JA (2021) The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer&#x2019;s dementia in older persons. Acta Neuropathol Commun 9(1):156. https://doi.org/10.1186/s40478-021-01260-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01260-0</ArticleId><ArticleId IdType="pubmed">34563269</ArticleId><ArticleId IdType="pmc">8466680</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E, Van Deerlin VM, Abner EL et al (2020) Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain 143(9):2844&#x2013;2857. https://doi.org/10.1093/brain/awaa219</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa219</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId><ArticleId IdType="pmc">7526723</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Barnes LL, Yu L, Wilson RS, Bennett DA, Schneider JA (2020) Limbic-predominant age-related TDP-43 encephalopathy in black and white decedents. Neurology. https://doi.org/10.1212/wnl.0000000000010602</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000010602</ArticleId><ArticleId IdType="pubmed">32759188</ArticleId><ArticleId IdType="pmc">7713750</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA et al (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE &#x3b5;4 haplotype status: a community-based cohort study. Lancet Neurol 17(9):773&#x2013;781. https://doi.org/10.1016/s1474-4422(18)30251-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30251-5</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId><ArticleId IdType="pmc">6154505</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S, Wei A, Jicha GA et al (2019) TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol Dis 125:67&#x2013;76. https://doi.org/10.1016/j.nbd.2019.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.01.013</ArticleId><ArticleId IdType="pubmed">30682540</ArticleId><ArticleId IdType="pmc">6696921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Schulz PE, Takei H, Rivera AL, Jackson RE, Roman G, Jicha GA et al (2017) Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With Sclerosis. Arch Pathol Lab Med 141(8):1113&#x2013;1126. https://doi.org/10.5858/arpa.2016-0469-SA</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2016-0469-SA</ArticleId><ArticleId IdType="pubmed">28467211</ArticleId><ArticleId IdType="pmc">5922266</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5:16. https://doi.org/10.1186/1750-1172-5-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-5-16</ArticleId><ArticleId IdType="pubmed">20525256</ArticleId><ArticleId IdType="pmc">2902432</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardis A, Zampieri S, Canterini S, Newell KL, Stuani C, Murrell JR, Ghetti B, Fiorenza MT et al (2016) Altered localization and functionality of TAR DNA Binding Protein 43 (TDP-43) in niemann- pick disease type C. Acta Neuropathol Commun 4(1):52. https://doi.org/10.1186/s40478-016-0325-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0325-4</ArticleId><ArticleId IdType="pubmed">27193329</ArticleId><ArticleId IdType="pmc">4870731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosunov A, Olabarria M, Goldman JE (2018) Alexander disease: an astrocytopathy that produces a leukodystrophy. Brain Pathol 28(3):388&#x2013;398. https://doi.org/10.1111/bpa.12601</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12601</ArticleId><ArticleId IdType="pubmed">29740945</ArticleId><ArticleId IdType="pmc">8028392</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A (2014) Astrocytic TDP-43 pathology in Alexander disease. J Neurosci 34(19):6448&#x2013;6458. https://doi.org/10.1523/jneurosci.0248-14.2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0248-14.2014</ArticleId><ArticleId IdType="pubmed">24806671</ArticleId><ArticleId IdType="pmc">4012304</ArticleId></ArticleIdList></Reference><Reference><Citation>Jany PL, Hagemann TL, Messing A (2013) GFAP expression as an indicator of disease severity in mouse models of Alexander disease. ASN Neuro 5(1):e00109. https://doi.org/10.1042/an20130003</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/an20130003</ArticleId><ArticleId IdType="pubmed">23432455</ArticleId><ArticleId IdType="pmc">3604736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao J, Wu H, Lin Q, Wei W, Lu XH, Cantle JP, Ao Y, Olsen RW et al (2011) Deletion of astroglial Dicer causes non-cell-autonomous neuronal dysfunction and degeneration. J Neurosci 31(22):8306&#x2013;8319. https://doi.org/10.1523/jneurosci.0567-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0567-11.2011</ArticleId><ArticleId IdType="pubmed">21632951</ArticleId><ArticleId IdType="pmc">3500097</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Fujioka S, Traynor S, Soto-Ortolaza AI, Petrucelli L, Dickson DW, Rademakers R, Boylan KB et al (2013) TARDBP mutations in Parkinson&#x2019;s disease. Parkinsonism Relat Disord 19(3):312&#x2013;315. https://doi.org/10.1016/j.parkreldis.2012.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2012.11.003</ArticleId><ArticleId IdType="pubmed">23231971</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114(3):221&#x2013;229. https://doi.org/10.1007/s00401-007-0261-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokoulina P, Rohn TT (2010) Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson&#x2019;s disease and dementia with Lewy bodies. Neurodegener Dis 7(4):243&#x2013;250. https://doi.org/10.1159/000287952</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000287952</ArticleId><ArticleId IdType="pubmed">20551689</ArticleId><ArticleId IdType="pmc">2895743</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O, Davidson Y, Arai T, Hasegawa M, Akiyama H, Ishizu H, Terada S, Sikkink S et al (2010) Effect of topographical distribution of &#x3b1;-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathol 120(6):789&#x2013;801. https://doi.org/10.1007/s00401-010-0731-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0731-9</ArticleId><ArticleId IdType="pubmed">20669025</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O et al (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res 1184:284&#x2013;294. https://doi.org/10.1016/j.brainres.2007.09.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J (2017) TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol 27(4):472&#x2013;479. https://doi.org/10.1111/bpa.12424</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M et al (2009) Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol 117(2):125&#x2013;136. https://doi.org/10.1007/s00401-008-0480-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292&#x2013;1295. https://doi.org/10.1126/science.1101738</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1101738</ArticleId><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehay B, Bov&#xe9; J, Rodr&#xed;guez-Muela N, Perier C, Recasens A, Boya P, Vila M (2010) Pathogenic lysosomal depletion in Parkinson&#x2019;s disease. J Neurosci 30(37):12535&#x2013;12544. https://doi.org/10.1523/jneurosci.1920-10.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.1920-10.2010</ArticleId><ArticleId IdType="pubmed">20844148</ArticleId><ArticleId IdType="pmc">6633458</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T et al (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 44(3):415&#x2013;422. https://doi.org/10.1002/ana.410440324</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410440324</ArticleId><ArticleId IdType="pubmed">9749615</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Lin WL, Walton RL, Ross OA, Dickson DW (2018) TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and &#x3b1;-synuclein in glial cytoplasmic inclusions. Neuropathol Appl Neurobiol 44(7):707&#x2013;721. https://doi.org/10.1111/nan.12485</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12485</ArticleId><ArticleId IdType="pubmed">29660838</ArticleId><ArticleId IdType="pmc">6191374</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Malunda JA, Hurtig HI, Duda JE, Wenning GK, Gilman S, Low PA, Lee VM et al (2011) TDP-43 pathology occurs infrequently in multiple system atrophy. Neuropathol Appl Neurobiol 37(4):358&#x2013;365. https://doi.org/10.1111/j.1365-2990.2010.01136.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2010.01136.x</ArticleId><ArticleId IdType="pubmed">20942898</ArticleId><ArticleId IdType="pmc">3030620</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Wszolek ZK et al (2017) Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord 32(2):246&#x2013;255. https://doi.org/10.1002/mds.26809</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26809</ArticleId><ArticleId IdType="pubmed">28009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, Hasegawa M, Akiyama H et al (2010) Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol 120(1):55&#x2013;66. https://doi.org/10.1007/s00401-010-0702-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0702-1</ArticleId><ArticleId IdType="pubmed">20512649</ArticleId><ArticleId IdType="pmc">2901929</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67(6):555&#x2013;564. https://doi.org/10.1097/NEN.0b013e31817713b5</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE et al (2018) Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol 136(3):389&#x2013;404. https://doi.org/10.1007/s00401-018-1878-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1878-z</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId><ArticleId IdType="pmc">6309287</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouri N, Oshima K, Takahashi M, Murray ME, Ahmed Z, Parisi JE, Yen SH, Dickson DW (2013) Corticobasal degeneration with olivopontocerebellar atrophy and TDP-43 pathology: an unusual clinicopathologic variant of CBD. Acta Neuropathol 125(5):741&#x2013;752. https://doi.org/10.1007/s00401-013-1087-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1087-8</ArticleId><ArticleId IdType="pubmed">23371366</ArticleId><ArticleId IdType="pmc">3633676</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ, Mitchell JC, Novoselov S, Miller J, Nishimura AL, Scotter EL, Vance CA, Cheetham ME et al (2016) The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. Brain 139(Pt 5):1417&#x2013;1432. https://doi.org/10.1093/brain/aww028</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww028</ArticleId><ArticleId IdType="pubmed">26936937</ArticleId><ArticleId IdType="pmc">4845254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tefera TW, Steyn FJ, Ngo ST, Borges K (2021) CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target? Cell Biosci 11(1):14. https://doi.org/10.1186/s13578-020-00511-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-020-00511-2</ArticleId><ArticleId IdType="pubmed">33431046</ArticleId><ArticleId IdType="pmc">7798275</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Prats E, Martinez-Gonzalez L, Gonzalo-Consuegra C, Liachko NF, Perez C, Ram&#xed;rez D, Kraemer BC, Martin-Requero &#xc1;, et al (2020) Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem:112968. doi: https://doi.org/10.1016/j.ejmech.2020.112968</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>